BMB Reports

Korean Society for Biochemistry and Molecular Biology (생화학분자생물학회)
권호 표지
DOI QR코드

DOI QR Code

Up-regulation of HOXB cluster genes are epigenetically regulated in tamoxifen-resistant MCF7 breast cancer cells

  • Yang, Seoyeon (Department of Anatomy, Embryology Laboratory, Yonsei University College of Medicine) ;
  • Lee, Ji-Yeon (Department of Anatomy, Embryology Laboratory, Yonsei University College of Medicine) ;
  • Hur, Ho (Department of Surgery, National Health Insurance Service Ilsan Hospital) ;
  • Oh, Ji Hoon (Department of Anatomy, Embryology Laboratory, Yonsei University College of Medicine) ;
  • Kim, Myoung Hee (Department of Anatomy, Embryology Laboratory, Yonsei University College of Medicine)
  • Received : 2018.01.30
  • Accepted : 2018.04.26
  • Published : 2018.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Tamoxifen (TAM) is commonly used to treat estrogen receptor (ER)-positive breast cancer. Despite the remarkable benefits, resistance to TAM presents a serious therapeutic challenge. Since several HOX transcription factors have been proposed as strong candidates in the development of resistance to TAM therapy in breast cancer, we generated an in vitro model of acquired TAM resistance using ER-positive MCF7 breast cancer cells (MCF7-TAMR), and analyzed the expression pattern and epigenetic states of HOX genes. HOXB cluster genes were uniquely up-regulated in MCF7-TAMR cells. Survival analysis of in slico data showed the correlation of high expression of HOXB genes with poor response to TAM in ER-positive breast cancer patients treated with TAM. Gain- and loss-of-function experiments showed that the overexpression of multi HOXB genes in MCF7 renders cancer cells more resistant to TAM, whereas the knockdown restores TAM sensitivity. Furthermore, activation of HOXB genes in MCF7-TAMR was associated with histone modifications, particularly the gain of H3K9ac. These findings imply that the activation of HOXB genes mediate the development of TAM resistance, and represent a target for development of new strategies to prevent or reverse TAM resistance.

Keywords

References

  1. Clark GM, Osborne CK and McGuire WL (1984) Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol 2, 1102-1109 https://doi.org/10.1200/JCO.1984.2.10.1102
  2. Shang Y, Hu X, DiRenzo J, Lazar MA and Brown M (2000) Cofactor dynamics and sufficiency in estrogen receptorregulated transcription. Cell 103, 843-852 https://doi.org/10.1016/S0092-8674(00)00188-4
  3. Osborne CK (1998) Tamoxifen in the treatment of breast cancer. N Engl J Med 339, 1609-1618 https://doi.org/10.1056/NEJM199811263392207
  4. Early Breast Cancer Trialists' Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365,1687-1717 https://doi.org/10.1016/S0140-6736(05)66544-0
  5. Garcia-Becerra R, Santos N, Diaz L and Camacho J (2012) Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance. Int J Mol Sci 14, 108-145 https://doi.org/10.3390/ijms14010108
  6. Musgrove EA and Sutherland RL (2009) Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 9, 631-643 https://doi.org/10.1038/nrc2713
  7. Wang KC, Helms JA and Chang HY (2009) Regeneration, repair and remembering identity: the three Rs of Hox gene expression. Trends Cell Biol 19, 268-275 https://doi.org/10.1016/j.tcb.2009.03.007
  8. Bhatlekar S, Fields JZ and Boman BM (2014) HOX genes and their role in the development of human cancers. J Mol Med (Berl) 92, 811-823 https://doi.org/10.1007/s00109-014-1181-y
  9. Shah N and Sukumar S (2010) The Hox genes and their roles in oncogenesis. Nat Rev Cancer 10, 361-371 https://doi.org/10.1038/nrc2826
  10. Svingen T and Tonissen KF (2003) Altered HOX gene expression in human skin and breast cancer cells. Cancer Biol Ther 2, 518-523 https://doi.org/10.4161/cbt.2.5.441
  11. Cantile M, Pettinato G, Procino A, Feliciello I, Cindolo L and Cillo C (2003) In vivo expression of the whole HOX gene network in human breast cancer. Eur J Cancer 39, 257-264 https://doi.org/10.1016/S0959-8049(02)00599-3
  12. Makiyama K, Hamada J, Takada M et al (2005) Aberrant expression of HOX genes in human invasive breast carcinoma. Oncol Rep 13, 673-679
  13. Morgan R, Boxall A, Harrington KJ et al (2012) Targeting the HOX/PBX dimer in breast cancer. Breast Cancer Res Treat 136, 389-398 https://doi.org/10.1007/s10549-012-2259-2
  14. Hur H, Lee JY, Yun HJ, Park BW and Kim MH (2014) Analysis of HOX gene expression patterns in human breast cancer. Mol Biotechnol 56, 64-71 https://doi.org/10.1007/s12033-013-9682-4
  15. Jin K and Sukumar S (2016) HOX genes: Major actors in resistance to selective endocrine response modifiers. Biochim Biophys Acta 1865, 105-110
  16. Lee JY, Hur H, Yun HJ et al (2015) HOXB5 promotes the proliferation and invasion of breast cancer cells. Int J Biol Sci 11, 701-711 https://doi.org/10.7150/ijbs.11431
  17. Jin K, Kong X, Shah T et al (2012) The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway. Proc Natl Acad Sci U S A 109, 2736-2741 https://doi.org/10.1073/pnas.1018859108
  18. Jin K, Park S, Teo WW et al (2015) HOXB7 Is an ERalpha cofactor in the activation of HER2 and multiple ER target genes leading to endocrine resistance. Cancer Discov 5, 944-959 https://doi.org/10.1158/2159-8290.CD-15-0090
  19. Shah N, Jin K, Cruz LA et al (2013) HOXB13 mediates tamoxifen resistance and invasiveness in human breast cancer by suppressing ERalpha and inducing IL-6 expression. Cancer Res 73, 5449-5458 https://doi.org/10.1158/0008-5472.CAN-13-1178
  20. Barber BA and Rastegar M (2010) Epigenetic control of Hox genes during neurogenesis, development, and disease. Ann Anat 192, 261-274 https://doi.org/10.1016/j.aanat.2010.07.009
  21. Srivastava S, Dhawan J and Mishra RK (2015) Epigenetic mechanisms and boundaries in the regulation of mammalian Hox clusters. Mech Deve 138 Pt 2, 160-169 https://doi.org/10.1016/j.mod.2015.07.015
  22. Daftary GS and Taylor HS (2006) Endocrine regulation of HOX genes. Endocr Rev 27, 331-355 https://doi.org/10.1210/er.2005-0018
  23. Cakmak H and Taylor HS (2010) Molecular mechanisms of treatment resistance in endometriosis: the role of progesterone-hox gene interactions. Semin Reprod Med 28, 69-74 https://doi.org/10.1055/s-0029-1242996
  24. Iorio MV, Casalini P, Piovan C, Braccioli L and Tagliabue E (2011) Breast cancer and microRNAs: therapeutic impact. Breast 20 Suppl 3, S63-70
  25. Xin F, Li M, Balch C et al (2009) Computational analysis of microRNA profiles and their target genes suggests significant involvement in breast cancer antiestrogen resistance. Bioinformatics 25, 430-434 https://doi.org/10.1093/bioinformatics/btn646
  26. Hoppe R, Achinger-Kawecka J, Winter S et al (2013) Increased expression of miR-126 and miR-10a predict prolonged relapse-free time of primary oestrogen receptorpositive breast cancer following tamoxifen treatment. Eur J Cancer 49, 3598-3608 https://doi.org/10.1016/j.ejca.2013.07.145
  27. Jansen MP, Knijnenburg T, Reijm EA et al (2013) Hallmarks of aromatase inhibitor drug resistance revealed by epigenetic profiling in breast cancer. Cancer Res 73, 6632-6641 https://doi.org/10.1158/0008-5472.CAN-13-0704
  28. Nguyen VT, Barozzi I, Faronato M et al (2015) Differential epigenetic reprogramming in response to specific endocrine therapies promotes cholesterol biosynthesis and cellular invasion. Nat Commun 6, 10044 https://doi.org/10.1038/ncomms10044
  29. di Pietro M, Lao-Sirieix P, Boyle S et al (2012) Evidence for a functional role of epigenetically regulated midcluster HOXB genes in the development of Barrett esophagus. Proc Natl Acad Sci U S A 109, 9077-9082 https://doi.org/10.1073/pnas.1116933109
  30. Misteli T (2010) Higher-order genome organization in human disease. Cold Spring Harb Perspect Biol 2, a000794
  31. Deng C, Li Y, Zhou L et al (2016) HoxBlinc RNA recruits Set1/MLL complexes to activate Hox gene expression patterns and mesoderm lineage development. Cell Rep 14, 103-114 https://doi.org/10.1016/j.celrep.2015.12.007